Nanopharm Ltd., an Aptar Pharma company and a provider of contract research and development services for orally inhaled and nasal drug products (OINDPs), has announced expansion plans to better support increased customer needs. The new facility in Cwmbran, Wales will create an estimated 60 new employment opportunities and allow Nanopharm to substantially increase its full services capacity, including the expansion of its formulation and analytical capabilities, to facilitate the rapid growth of its business.
Nanopharm has signed a long-term lease on a nearby building that is four times larger than its current premises in Newport, Wales. At 25,000 sq. ft. and spanning three floors, the facility has been completely redesigned to house state-of-the-art research and development (R&D), and analytical laboratories, with construction expected to be completed in early 2022.
Building on the company’s heritage and belief that fundamental materials science drives behavior in aerosol science, the addition of new characterization and analytical capabilities as well as increased capacity will enable Nanopharm’s scientists to provide specialist services, benefit from in-house evaluation and facilitate the customers’ desire to get to the clinic quickly, yet safely. The new analytical laboratories will also be cGMP compliant to allow Nanopharm to further support its customers through their new product development process.
In-house particle engineering capabilities will be significantly expanded, including the installation of a one-of-a-kind spray dryer with world-class flexibility and scalability to multiple commercial platforms. Moreover, Nanopharm will have access to a range of new micronization techniques to enable unique formulation approaches for sensitive molecules including biologics, as well as the manufacture of complex suspensions and powders including nanoparticles for both inhaled and nasal products.
Plans also include the addition of a potent suite giving Nanopharm the ability to handle OEB (Occupational Exposure Band) Class 5 compounds, BSL (Biosafety Level) Class 2 biological materials and a license to handle Schedule 1-5 controlled substances, which aligns with the direction and needs of the industry.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!